661 related articles for article (PubMed ID: 12751917)
1. Vaccines for Alzheimer's disease: how close are we?
Janus C
CNS Drugs; 2003; 17(7):457-74. PubMed ID: 12751917
[TBL] [Abstract][Full Text] [Related]
2. Vaccination strategies for Alzheimer's disease: A new hope?
Woodhouse A; Dickson TC; Vickers JC
Drugs Aging; 2007; 24(2):107-19. PubMed ID: 17313199
[TBL] [Abstract][Full Text] [Related]
3. Amyloid-beta immunotherapy for Alzheimer's disease.
Fu HJ; Liu B; Frost JL; Lemere CA
CNS Neurol Disord Drug Targets; 2010 Apr; 9(2):197-206. PubMed ID: 20205640
[TBL] [Abstract][Full Text] [Related]
4. An Aβ3-10-KLH vaccine reduced Alzheimer's disease-like pathology and had a sustained effect in Tg-APPswe/PSEN1dE9 mice.
Meng Y; Ding L; Zhang HY; Yin WC; Yan Y; Cao YP
Brain Res; 2017 Oct; 1673():72-77. PubMed ID: 28779977
[TBL] [Abstract][Full Text] [Related]
5. Vaccination of Alzheimer's model mice with Abeta derivative in alum adjuvant reduces Abeta burden without microhemorrhages.
Asuni AA; Boutajangout A; Scholtzova H; Knudsen E; Li YS; Quartermain D; Frangione B; Wisniewski T; Sigurdsson EM
Eur J Neurosci; 2006 Nov; 24(9):2530-42. PubMed ID: 17100841
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic Vaccine Based on Pyroglutamate-3 Amyloid β Generates Strong Antibody Response and Rescues Cognitive Decline in Alzheimer's Disease Model Mice.
Li G; Hu ZW; Chen PG; Sun ZY; Chen YX; Zhao YF; Li YM
ACS Chem Neurosci; 2017 Mar; 8(3):454-459. PubMed ID: 28292186
[TBL] [Abstract][Full Text] [Related]
7. Strikingly reduced amyloid burden and improved behavioral performance in Alzheimer's disease mice immunized with recombinant chimeric vaccines by hexavalent foldable Aβ₁₋₁₅ fused to toxin-derived carrier proteins.
Yu YZ; Wang WB; Chen A; Chang Q; Liu S; Zhao M; Wang S; Qiu WY; Pang XB; Xu Q; Sun ZW
J Alzheimers Dis; 2014; 41(1):243-60. PubMed ID: 24625800
[TBL] [Abstract][Full Text] [Related]
8. Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer's disease.
Camboni M; Wang CM; Miranda C; Yoon JH; Xu R; Zygmunt D; Kaspar BK; Martin PT
Neurobiol Dis; 2014 Feb; 62():31-43. PubMed ID: 24021662
[TBL] [Abstract][Full Text] [Related]
9. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
Boche D; Denham N; Holmes C; Nicoll JA
Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
[TBL] [Abstract][Full Text] [Related]
10. 'Clinical trials in Alzheimer's disease': immunotherapy approaches.
Delrieu J; Ousset PJ; Caillaud C; Vellas B
J Neurochem; 2012 Jan; 120 Suppl 1():186-193. PubMed ID: 21883222
[TBL] [Abstract][Full Text] [Related]
11. Novel Abeta immunogens: is shorter better?
Lemere CA; Maier M; Peng Y; Jiang L; Seabrook TJ
Curr Alzheimer Res; 2007 Sep; 4(4):427-36. PubMed ID: 17908047
[TBL] [Abstract][Full Text] [Related]
12. Vaccine development for Alzheimer's disease.
Dasilva KA; Aubert I; McLaurin J
Curr Pharm Des; 2006; 12(33):4283-93. PubMed ID: 17105428
[TBL] [Abstract][Full Text] [Related]
13. [Abeta vaccine therapy for Alzheimer's disease].
Hara H
Rinsho Shinkeigaku; 2005 Nov; 45(11):867-9. PubMed ID: 16447748
[TBL] [Abstract][Full Text] [Related]
14. Antibodies from a DNA peptide vaccination decrease the brain amyloid burden in a mouse model of Alzheimer's disease.
Schiltz JG; Salzer U; Mohajeri MH; Franke D; Heinrich J; Pavlovic J; Wollmer MA; Nitsch RM; Moelling K
J Mol Med (Berl); 2004 Oct; 82(10):706-14. PubMed ID: 15241501
[TBL] [Abstract][Full Text] [Related]
15. Intracerebroventricular passive immunization in transgenic mouse models of Alzheimer's disease.
Chauhan NB; Siegel GJ
Expert Rev Vaccines; 2004 Dec; 3(6):717-25. PubMed ID: 15606357
[TBL] [Abstract][Full Text] [Related]
16. Reduction of beta-amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization.
Frenkel D; Dewachter I; Van Leuven F; Solomon B
Vaccine; 2003 Mar; 21(11-12):1060-5. PubMed ID: 12559780
[TBL] [Abstract][Full Text] [Related]
17. Butyrylcholinesterase-knockout reduces fibrillar β-amyloid and conserves
DeBay DR; Reid GA; Macdonald IR; Mawko G; Burrell S; Martin E; Bowen CV; Darvesh S
Brain Res; 2017 Sep; 1671():102-110. PubMed ID: 28729192
[TBL] [Abstract][Full Text] [Related]
18. Immunization with the SDPM1 peptide lowers amyloid plaque burden and improves cognitive function in the APPswePSEN1(A246E) transgenic mouse model of Alzheimer's disease.
Wang CM; Devries S; Camboni M; Glass M; Martin PT
Neurobiol Dis; 2010 Sep; 39(3):409-22. PubMed ID: 20493257
[TBL] [Abstract][Full Text] [Related]
19. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice.
Ding L; Meng Y; Zhang HY; Yin WC; Yan Y; Cao YP
Neurosci Lett; 2016 Nov; 634():1-6. PubMed ID: 27693663
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for Alzheimer's disease: rational basis in ongoing clinical trials.
Menéndez-González M; Pérez-Piñera P; Martínez-Rivera M; Muñiz AL; Vega JA
Curr Pharm Des; 2011; 17(5):508-20. PubMed ID: 21375481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
